Literature DB >> 17166848

Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis.

Marc E Lenburg1, Anupama Sinha2, Douglas V Faller2, Gerald V Denis3.   

Abstract

The dual bromodomain protein Brd2 is closely related to the basal transcription factor TAF(II)250, which is essential for cyclin A transactivation and mammalian cell cycle progression. In transgenic mice, constitutive lymphoid expression of Brd2 causes a malignancy most similar to human diffuse large B cell lymphoma. We compare the genome-wide transcriptional expression profiles of these lymphomas with those of proliferating and resting normal B cells. Transgenic tumors reproducibly show differential expression of a large number of genes important for cell cycle control and lymphocyte biology; expression patterns are either tumor-specific or proliferation-specific. Several of their human orthologs have been implicated in human lymphomagenesis. Others correlate with human disease survival time. BRD2 is underexpressed in some subtypes of human lymphoma and these subtypes display a number of similarities to the BRD2-mediated murine tumors. We illustrate with a high degree of detail that cancer is more than rampant cellular proliferation, but involves the additional transcriptional mobilization of many genes, some of them poorly characterized, which show a tumor-specific pattern of gene expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17166848      PMCID: PMC2819333          DOI: 10.1074/jbc.M605870200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  Bromodomain motifs and "scaffolding"?

Authors:  G V Denis
Journal:  Front Biosci       Date:  2001-09-01

Review 2.  The bromodomain: a regulator of ATP-dependent chromatin remodeling?

Authors:  P J Horn; C L Peterson
Journal:  Front Biosci       Date:  2001-08-01

3.  A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition.

Authors:  A Dey; J Ellenberg; A Farina; A E Coleman; T Maruyama; S Sciortino; J Lippincott-Schwartz; K Ozato
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  Structure and ligand of a histone acetyltransferase bromodomain.

Authors:  C Dhalluin; J E Carlson; L Zeng; C He; A K Aggarwal; M M Zhou
Journal:  Nature       Date:  1999-06-03       Impact factor: 49.962

5.  Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia.

Authors:  C Lavau; C Du; M Thirman; N Zeleznik-Le
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

Review 6.  Retroviral transduction model of mixed lineage leukemia fused to CREB binding protein.

Authors:  D Liedman; N Zeleznik-Le
Journal:  Curr Opin Hematol       Date:  2001-07       Impact factor: 3.284

Review 7.  You bet-cha: a novel family of transcriptional regulators.

Authors:  B Florence; D V Faller
Journal:  Front Biosci       Date:  2001-08-01

8.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

9.  RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F.

Authors:  G V Denis; C Vaziri; N Guo; D V Faller
Journal:  Cell Growth Differ       Date:  2000-08

Review 10.  Diffuse large-cell lymphomas: a review of therapy.

Authors:  J E Godwin; R I Fisher
Journal:  Clin Lymphoma       Date:  2001-12
View more
  20 in total

Review 1.  Bromodomain coactivators in cancer, obesity, type 2 diabetes, and inflammation.

Authors:  Gerald V Denis
Journal:  Discov Med       Date:  2010-12       Impact factor: 2.970

2.  High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.

Authors:  Yago Nieto; Peter Thall; Ben Valdez; Borje Andersson; Uday Popat; Paolo Anderlini; Elizabeth J Shpall; Roland Bassett; Amin Alousi; Chitra Hosing; Partow Kebriaei; Muzaffar Qazilbash; Erin Frazier; Alison Gulbis; Christina Chancoco; Qaiser Bashir; Stefan Ciurea; Issa Khouri; Simrit Parmar; Nina Shah; Laura Worth; Gabriela Rondon; Richard Champlin; Roy B Jones
Journal:  Biol Blood Marrow Transplant       Date:  2012-05-27       Impact factor: 5.742

Review 3.  BET domain co-regulators in obesity, inflammation and cancer.

Authors:  Anna C Belkina; Gerald V Denis
Journal:  Nat Rev Cancer       Date:  2012-06-22       Impact factor: 60.716

4.  Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.

Authors:  Paul B Romesser; David H Perlman; Douglas V Faller; Catherine E Costello; Mark E McComb; Gerald V Denis
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

Review 5.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

6.  Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling.

Authors:  Jihyun Chung; Vrajesh Karkhanis; Robert A Baiocchi; Saïd Sif
Journal:  J Biol Chem       Date:  2019-03-18       Impact factor: 5.157

7.  Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.

Authors:  Gang Chen; Paritosh Ghosh; Thomas O'Farrell; Rachel Munk; Louis J Rezanka; Carl Y Sasaki; Dan L Longo
Journal:  J Biol Chem       Date:  2012-05-23       Impact factor: 5.157

8.  Expression and function of a novel isoform of Sox5 in malignant B cells.

Authors:  Shanique K E Edwards; Anand Desai; Yan Liu; Carissa R Moore; Ping Xie
Journal:  Leuk Res       Date:  2013-12-25       Impact factor: 3.156

9.  The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis.

Authors:  Anna C Belkina; Wanda P Blanton; Barbara S Nikolajczyk; Gerald V Denis
Journal:  J Leukoc Biol       Date:  2013-12-06       Impact factor: 4.962

Review 10.  Clinical trials for BET inhibitors run ahead of the science.

Authors:  Guillaume Andrieu; Anna C Belkina; Gerald V Denis
Journal:  Drug Discov Today Technol       Date:  2016-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.